Teva has closed its acquisition of Emalex Biosciences, adding late‑stage Tourette syndrome candidate ecopipam to its neuroscience portfolio and advancing its “Pivot to Growth” strategy.
The deal, first announced alongside Teva’s Q1 update, brings in ecopipam, a first‑in‑class selective dopamine D1 receptor antagonist in development for pediatric Tourette syndrome, an area of significant unmet need. Ecopipam has secured FDA Orphan Drug and Fast Track designations, and Phase 3 data were recently published in JAMA Neurology, with a U.S. NDA filing planned for the second half of 2026.
At closing, Teva paid Emalex shareholders upfront consideration of 700 million dollars, with the potential for up to 200 million dollars in additional commercial milestone payments plus net sales–based royalties, contingent on regulatory approval and successful commercialization. The structure aligns with Teva’s stated goal of pursuing “capital‑efficient” business development to build its innovative pipeline.
Chief executive Richard Francis framed the acquisition as a tangible example of Teva’s strategy to rebalance away from a predominantly generics‑driven model toward higher‑growth innovative assets. With ecopipam now in‑house, Teva gains a late‑stage neurology program that, if approved, could support both near‑term revenue growth and longer‑term positioning in movement disorders.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!